AGN Stock Analysis: Aegon | AS
Insurance - Diversified | AS, Netherlands | Market Cap: 11.716m EUR | 12M Return: 26.8% | BMG0112X1056 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 29.7M
Qual. Beats: 0
Rev. Trend: -21.9%
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Aegon Ltd. (ticker: AGN), listed on the Amsterdam stock exchange (AS), is a large-cap Dutch financial services group operating in the insurance and retirement space across the Americas, the Netherlands, the United Kingdom, and other international markets. The company was founded in 1844 and is headquartered in Schiphol, the Netherlands.
Its product portfolio spans retirement plans, mutual funds, unit-linked products, annuities, and life and health insurance, with distribution concentrated under the Transamerica brand (notably in the United States) and the World Financial Group brand. Aegon is classified under the GICS Multi-line Insurance sub-industry, reflecting its mix of life insurance, retirement, and asset management offerings rather than a focus on property and casualty lines.
As a multi-line insurance provider, Aegons business model is built on collecting premiums and retirement contributions, managing long-duration investment portfolios, and generating fee-based income from asset management activities. The companys geographic and product diversification is typical of European insurance groups that have expanded into the US retirement market.
- Higher US rates lift Transamerica net investment income margins
- Variable annuity hedge gains reduce earnings volatility and capital strain
- Capital returns accelerate via buybacks and dividends after US asset sales
- UK and Dutch pension reforms drive fee-based retirement inflows
| Net Income: 1.01b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.00 > 0.02 and ΔFCF/TA 0.28 > 1.0 |
| NWC/Revenue: 105.4% < 20% (prev 205.4%; Δ -100.1% < -1%) |
| CFO/TA 0.00 > 3% & CFO 235.0m > Net Income 1.01b |
| Net Debt (507.0m) to EBITDA (1.12b): 0.45 < 3 |
| Current Ratio: error (cannot be calculated; needs correct Total Current Assets and Liabilities) |
| Outstanding Shares: last quarter (1.57b) vs 12m ago -5.95% < -2% |
| Gross Margin: -6.84% > 18% (prev 27.53%; Δ -34.36% > 0.5%) |
| Asset Turnover: 6.12% > 50% (prev 7.39%; Δ -1.27% > 0%) |
| Interest Coverage Ratio: 4.23 > 6 (EBIT TTM 1.27b / Interest Expense TTM 300.0m) |
| A: 0.06 (Total Current Assets 20.9b - Total Current Liabilities 0.0) / Total Assets 338b |
| B: 0.01 (Retained Earnings 3.89b / Total Assets 338b) |
| C: 0.00 (EBIT TTM 1.27b / Avg Total Assets 324b) |
| D: 0.03 (Book Value of Equity 8.91b / Total Liabilities 329b) |
| Altman-Z'' = 0.50 = B |
| DSRI: 3.0 (Receivables 17.4b/3.83b, Revenue 19.8b/22.9b) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 1.14 (AQ_t 0.94 / AQ_t-1 0.82) |
| SGI: 0.86 (Revenue 19.8b / 22.9b) |
| TATA: 0.00 (NI 1.01b - CFO 235.0m) / TA 338b) |
| Beneish M = -1.39 (Cap -4..+1) = D |
As of August 31, 2026, the stock is trading at EUR 8.03 with a total of 3,782,158 shares traded. Over the past week, the price has changed by +3.48%, over one month by -1.81%, over three months by +13.88% and over the past year by +26.76%.
Current recommended Stop Loss: 7.70 (which is 4.1% or 2.5 ATR below the current price).
Aegon has no consensus analysts rating.
P/E Trailing = 12.1385
P/E Forward = 10.4822
P/S = 1.0031
P/B = 1.3268
P/EG = 14.2828
Revenue TTM = 19.8b EUR
EBIT TTM = 1.27b EUR
EBITDA TTM = 1.12b EUR
Long Term Debt = 3.53b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 41.0m EUR (from shortTermDebt, last fiscal year)
Debt = 4.02b EUR (from shortLongTermDebtTotal, last quarter) + Leases 187.0m
Net Debt = 507.0m EUR (calculated: Debt 4.02b - CCE 3.52b)
Enterprise Value = 12.2b EUR (11.7b + Debt 4.02b - CCE 3.52b)
Interest Coverage Ratio = 4.23 (Ebit TTM 1.27b / Interest Expense TTM 300.0m)
EV/FCF = 61.11x (Enterprise Value 12.2b / FCF TTM 200.0m)
FCF Yield = 1.64% (FCF TTM 200.0m / Enterprise Value 12.2b)
FCF Margin = 1.01% (FCF TTM 200.0m / Revenue TTM 19.8b)
Net Margin = 5.07% (Net Income TTM 1.01b / Revenue TTM 19.8b)
Gross Margin = -6.84% ((Revenue TTM 19.8b - Cost of Revenue TTM 21.2b) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 0.04 (Enterprise Value 12.2b / Total Assets 338b)
Interest Expense / Debt = 7.46% (Interest Expense 300.0m / Debt 4.02b)
Taxrate = 4.02% (39.0m / 969.0m)
NOPAT = 1.22b (EBIT 1.27b * (1 - 4.02%))
Current Ratio = unknown (Total Current Assets 20.9b / Total Current Liabilities 0.0)
Debt / Equity = 0.45 (Debt 4.02b / totalStockholderEquity, last quarter 8.91b)
Debt / EBITDA = 0.45 (Net Debt 507.0m / EBITDA 1.12b)
Debt / FCF = 2.54 (Net Debt 507.0m / FCF TTM 200.0m)
Total Stockholder Equity = 8.72b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.31% (Net Income 1.01b / Total Assets 338b)
RoE = 11.53% (Net Income TTM 1.01b / Total Stockholder Equity 8.72b)
RoCE = 10.35% (EBIT 1.27b / Capital Employed (Equity 8.72b + L.T.Debt 3.53b))
RoIC = 0.38% (EBIT 1.27b / (Assets 338b - Curr.Liab 0.0 - Cash 3.52b))
WACC = 8.40% (E(11.7b)/V(15.7b) * Re(8.82%) + D(4.02b)/V(15.7b) * Rd(7.46%) * (1-Tc(0.04)))
Discount Rate = 8.82% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -73.62 | Cagr: -9.05%
[DCF] Terminal Value 75.28% ; FCFF base≈200.0m ; Y1≈200.8m ; Y5≈212.7m
[DCF] Fair Price = 1.88 (EV 3.28b - Net Debt 507.0m = Equity 2.78b / Shares 1.48b; r=8.40% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: -21.90 | Revenue CAGR: -4.64% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=0.89 | Chg30d=+0.69% | Revisions=+0% | GrowthEPS=+8.6% | GrowthRev=+1.1%
EPS next Year (2027-12-31): EPS=0.92 | Chg30d=-0.43% | Revisions=+0% | GrowthEPS=+3.0% | GrowthRev=+2.0%
[Analyst] Revisions Ratio: +0% (up=0, down=0)